4.7 Article

Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis

Journal

VACCINES
Volume 9, Issue 3, Pages -

Publisher

MDPI
DOI: 10.3390/vaccines9030245

Keywords

tuberculosis; vaccine; model; affordability; budget; cost-effectiveness

Funding

  1. UKRI/MRC [MR/N013638/1]
  2. Welcome Trust [218261/Z/19/Z]
  3. NIH [1R01AI147321-01]
  4. EDTCP [RIA208D-2505B]
  5. UK MRC (SET Bloomsbury) [CCF17-7779]
  6. ESRC [ES/P008011/1]
  7. BMGF [OPP1084276, OPP1135288, INV-001754]
  8. WHO [2020/985800-0]
  9. Bill and Melinda Gates Foundation [TB MAC OPP1135288]
  10. Wellcome Trust [218261/Z/19/Z] Funding Source: Wellcome Trust
  11. MRC [1923346] Funding Source: UKRI

Ask authors/readers for more resources

New tuberculosis vaccines have shown great progress in development, with mass vaccination of adolescents/adults potentially contributing cost-effectively to global tuberculosis control goals. However, the budgetary feasibility of vaccine programs is crucial, and targeted vaccination may present a more affordable approach.
New tuberculosis vaccines have made substantial progress in the development pipeline. Previous modelling suggests that adolescent/adult mass vaccination may cost-effectively contribute towards achieving global tuberculosis control goals. These analyses have not considered the budgetary feasibility of vaccine programmes. We estimate the maximum total cost that the public health sectors in India and China should expect to pay to introduce a M72/AS01(E)-like vaccine deemed cost-effective at country-specific willingness to pay thresholds for cost-effectiveness. To estimate the total disability adjusted life years (DALYs) averted by the vaccination programme, we simulated a 50% efficacy vaccine providing 10-years of protection in post-infection populations between 2027 and 2050 in India and China using a dynamic transmission model of M. tuberculosis. We investigated two mass vaccination strategies, both delivered every 10-years achieving 70% coverage: Vaccinating adults and adolescents (age >= 10y), or only the most efficient 10-year age subgroup (defined as greatest DALYs averted per vaccine given). We used country-specific thresholds for cost-effectiveness to estimate the maximum total cost (C-max) a government should be willing to pay for each vaccination strategy. Adult/adolescent vaccination resulted in a C-max of $21 billion (uncertainty interval [UI]: 16-27) in India, and $15B (UI:12-29) in China at willingness to pay thresholds of $264/DALY averted and $3650/DALY averted, respectively. Vaccinating the highest efficiency age group (India: 50-59y; China: 60-69y) resulted in a C-max of $5B (UI:4-6) in India and $6B (UI:4-7) in China. Mass vaccination against tuberculosis of all adults and adolescents, deemed cost-effective, will likely impose a substantial budgetary burden. Targeted tuberculosis vaccination, deemed cost-effective, may represent a more affordable approach.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available